Study Description: The focus of this study is to evaluate the efficacy, safety, and tolerability of veliparib in women with previously untreated Stage III or IV, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Principal Investigator: Sharad Ghamande
Eligibility Criteria: Patients must have: Stage III or IV ovarian fallopian tube, or primary peritoneal cancer; Willing to undergo testing for gBRCA; Patients excluded patients who have received prior chemotherapy for any abdominal or pelvic tumor Please visit clinicaltrials.gove for a complete listing of the requirements.
Compensation: No, subjects will not be compensated.
If you don't see specific studies that interest you, please submit your contact information for future studies.